Literature DB >> 21793190

Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors.

William E Haskins1, Sruthi Eedala, Y L Avinash Jadhav, Manbir S Labhan, Vidya C Pericherla, Elizabeth J Perlman.   

Abstract

BACKGROUND: Childhood germ cell tumors (cGCTs), believed to arise from transformed primordial germ cells by an unknown mechanism, provide a unique model system for investigating cell signaling, pluripotency, and the microenvironment of neoplastic stem cells (NSCs) in vivo. This is the first report of proteomics of cGCTs. PROCEDURE: Four dysgerminomas (DYSs) and four childhood endodermal sinus tumors (cESTs), resembling self-renewing and differentiating NSCs, respectively, were selected. Proteomic studies were performed by 2-DE, SDS-PAGE, and cLC/MS/MS with protein database searching.
RESULTS: 2-DE: 9 of 941 spots were differentially regulated with greater than a twofold change in spot volume for at least three of four gels in each group. Two of nine spots had P values for the t-test analysis of comparisons less than 0.001, while the remaining spots had P values from 0.013 to 0.191. Top-ranked proteins were identified in nine of nine spots with 4.0-38% sequence coverage. APOA1, CRK, and PDIA3 were up-regulated in cESTs. TFG, TYMP, VCP, RBBP, FKBP4, and BiP were up-regulated in DYSs. SDS-PAGE: Up-regulation of NF45 and FKBP4 was observed in four of four cESTs and DYSs, respectively. The fold-changes observed correspond with characteristic genetic changes.
CONCLUSION: Differential regulation of FKBP4 and NF45, combined with previous research on immunosuppressant binding, suggests that glucocorticoid receptor signaling merits further investigation in cGCTs and NSCs.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793190      PMCID: PMC3204330          DOI: 10.1002/pbc.23282

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  50 in total

1.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

2.  Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

Authors:  Monica Brown Jones; Henry Krutzsch; Hungjun Shu; Yingming Zhao; Lance A Liotta; Elise C Kohn; Emmanuel F Petricoin
Journal:  Proteomics       Date:  2002-01       Impact factor: 3.984

3.  FK506-binding protein 52 phosphorylation: a potential mechanism for regulating steroid hormone receptor activity.

Authors:  Marc B Cox; Daniel L Riggs; Martin Hessling; Felix Schumacher; Johannes Buchner; David F Smith
Journal:  Mol Endocrinol       Date:  2007-08-23

4.  Stem cell factor as a novel diagnostic marker for early malignant germ cells.

Authors:  H Stoop; F Honecker; G J M van de Geijn; A J M Gillis; M C Cools; M de Boer; C Bokemeyer; K P Wolffenbuttel; S L S Drop; R R de Krijger; N Dennis; B Summersgill; A McIntyre; J Shipley; J W Oosterhuis; L H J Looijenga
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

5.  A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants.

Authors:  Antonio Rodríguez; Jagoree Roy; Sara Martínez-Martínez; María Dolores López-Maderuelo; Perla Niño-Moreno; Leticia Ortí; David Pantoja-Uceda; Antonio Pineda-Lucena; Martha S Cyert; Juan Miguel Redondo
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

6.  Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.

Authors:  Petra S Bachmann; Rosemary Gorman; Rachael A Papa; Jane E Bardell; Jette Ford; Ursula R Kees; Glenn M Marshall; Richard B Lock
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.

Authors:  L Gu; J Gao; Q Li; Y P Zhu; C S Jia; R Y Fu; Y Chen; Q K Liao; Z Ma
Journal:  Leukemia       Date:  2008-08-07       Impact factor: 11.528

8.  The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.

Authors:  Nicolas Pottier; Wenjian Yang; Mahfoud Assem; John C Panetta; Deqing Pei; Steven W Paugh; Cheng Cheng; Monique L Den Boer; Mary V Relling; Rob Pieters; William E Evans; Meyling H Cheok
Journal:  J Natl Cancer Inst       Date:  2008-12-09       Impact factor: 13.506

9.  Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor.

Authors:  Stefan Schmidt; Julie A E Irving; Lynne Minto; Elizabeth Matheson; Lindsay Nicholson; Andreas Ploner; Walther Parson; Anita Kofler; Melanie Amort; Martin Erdel; Andy Hall; Reinhard Kofler
Journal:  FASEB J       Date:  2006-10-31       Impact factor: 5.191

10.  Nuclear Receptors in Regulation of Mouse ES Cell Pluripotency and Differentiation.

Authors:  Eimear M Mullen; Peili Gu; Austin J Cooney
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more
  4 in total

Review 1.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

2.  Expression and Critical Role of Interleukin Enhancer Binding Factor 2 in Hepatocellular Carcinoma.

Authors:  Shaobing Cheng; Xu Jiang; Chaofeng Ding; Chengli Du; Kwabena Gyabaah Owusu-Ansah; Xiaoyu Weng; Wendi Hu; Chuanhui Peng; Zhen Lv; Rongliang Tong; Heng Xiao; Haiyang Xie; Lin Zhou; Jian Wu; Shusen Zheng
Journal:  Int J Mol Sci       Date:  2016-08-22       Impact factor: 5.923

3.  Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.

Authors:  Maria Braoudaki; George I Lambrou; Konstantinos Vougas; Kalliopi Karamolegou; George T Tsangaris; Fotini Tzortzatou-Stathopoulou
Journal:  J Hematol Oncol       Date:  2013-07-12       Impact factor: 17.388

4.  Serine hydroxymethyltransferase 2 (SHMT2) potentiates the aggressive process of oral squamous cell carcinoma by binding to interleukin enhancer-binding factor 2 (ILF2).

Authors:  Hui Zhang; Yilei Che; Bin Xuan; Xiaozhen Wu; Hui Li
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.